Opexa (Bilastine)

Bilastine works by competitively binding to peripheral H1 histamine receptors, blocking histamine from activating these receptors. This prevents the cascade of vascular leakage, nerve stimulation, and inflammatory mediator release that normally produces itching, redness, swelling, and other allergic signs.

The dosage of Opexa is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and renal function. Physicians tailor the regimen to achieve optimal symptom control while minimizing potential side effects.

Safety data for Bilastine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their doctor before starting Opexa.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Opexa (Bilastine) offers a high degree of selectivity for H1 receptors and minimal penetration of the central nervous system, which can reduce sedation compared with first‑generation antihistamines. Its efficacy in allergic conjunctivitis and urticaria is comparable to other second‑generation agents such as cetirizine or loratadine, while its side‑effect profile may be more favorable for patients sensitive to drowsiness.

Opexa should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Opexa is formulated for ocular administration. The prescribed number of drops is applied directly to the affected eye(s) as instructed by the healthcare provider, typically once or twice daily depending on the severity of symptoms.

Serious adverse reactions, although rare, include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, angioedema, and significant hepatic injury. Patients should seek immediate medical attention if they experience symptoms like swelling of the face, rash, or difficulty breathing.

Opexa is contraindicated in individuals with known hypersensitivity to Bilastine or any excipients in the formulation. Patients with a history of severe allergic reactions to antihistamines should avoid use, and those with significant renal impairment should be evaluated by a physician before starting therapy.